People with uncontrolled movement problems can have a harder time doing everyday tasks such as speaking, reading, writing, and cooking, which can cause a loss of independence. This may cause people to ...

Additional data to be presented examining the safety and tolerability of AUSTEDO during periods of titration and maintenance “Tardive dyskinesia causes involuntarily, uncontrollable movements, that ...

92% of patients with Huntington's disease (HD) chorea achieved optimal dosing by week 12 with treatment on the AUSTEDO 4-week patient titration kit according to early results from the START study ...

START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfaction AUSTEDO is the ...

Austedo (deutetrabenazine) and Ingrezza (valbenazine) are prescription drugs used to treat tardive dyskinesia and chorea associated with Huntington’s disease. Austedo and Ingrezza are not available as ...

Deutetrabenazine 6mg, 12mg, 18mg, 24mg, 30mg, 36mg, 42mg, 48mg; ext-rel tabs. Swallow whole. Take with or without food. Individualize. Initially 12mg once daily; may titrate at weekly intervals by 6mg ...

Austedo and Austedo XR treat tardive dyskinesia and chorea related to Huntington’s disease in adults. The dosage varies depending on the condition. Austedo typically starts at 6 mg twice daily.

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO ...